Effects of methotrexate on intraperiplasmic and axenic growth of Bdellovibrio bacteriovorus.
The intraperiplasmic growth rate and cell yield of wild-type Bdellovibrio bacteriovorus 109J, growing on Escherichia coli of normal composition as the substrate, were not markedly inhibited by 10-3 M methotrexate (4-amino-N10-methylpteroylglutamic acid). In contrast, the growth rate and cell yield of the mutant 109Ja, growing axenically in 0.5% yeast extract +0.15% peptone, were strongly inhibited by 10-4 and 10-3 M methotrexate. Thymine, thymidine, and thymidine-5'-monophosphate, in increasing order of effectiveness, partially or completely reversed the inhibition. E. coli depleted of tetrahydrofolate and having an abnormally high protein/deoxyribonucleic acid (DNA) ratio was obtained by growing it in the presence of methotrexate. B. bacteriovourus grew at a normal rate on these depleted E. coli cells but with somewhat reduced cell yield. Mexthotrexate (10-3 M) inhibited intraperiplasmic growth of bdellovibrio on the depleted E. coli somewhat more than it inhibited growth on normal E. coli, but the effects were small compared with inhibition of axenic growth of the  mutant. Total bdellovibrio DNA after growth on the depleted E. coli in the presence or absence of methotrexate exceeded the initial quanity of E. coli DNA present. Thymidine-5'-monophosphate (10-3 M) largely reversed the inhibition and increased the amount of net synthesis of DNA. The data are consistent with the prediction that intraperiplasmic growth of B. bacteriovorus should be insensitive to all metabolic inhibitors that act by specifically preventing synthesis of essential monomers. The data also indicate that B. bacteriovorus possesses thymidylate synthetase, thymidine phosphorylase, and thymidine kinase, and has the potential to carry out de novo DNA synthesis from non-DNA precursors during intraperiplasmic growth. The results also suggest that methionyl tRNAfMet is not required for initiation of protein synthesis by B. bacteriovorus.
D001419:Bacteria / Q000187:drug effects / Q000254:growth & development* / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D003470:Culture Media; D003593:Cytoplasm / Q000382:microbiology; D004269:DNA, Bacterial / Q000096:biosynthesis; D004336:Drug Antagonism; D004926:Escherichia coli / Q000378:metabolism / Q000648:ultrastructure; D008727:Methotrexate / Q000494:pharmacology*; D008858:Microscopy, Phase-Contrast; D009154:Mutation; D010461:Peptones; D012440:Saccharomyces; D013763:Tetrahydrofolates / Q000378:metabolism; D013936:Thymidine / Q000494:pharmacology; D013941:Thymine / Q000378:metabolism / Q000494:pharmacology; D013942:Thymine Nucleotides / Q000494:pharmacology
D003470:Culture Media; D004269:DNA, Bacterial; D010461:Peptones; D013763:Tetrahydrofolates; D013942:Thymine Nucleotides; D013941:Thymine; D013936:Thymidine; D008727:Methotrexate